FGFR3 and plasma cell myeloma: In multiple myeloma, FGFR3 inhibition has shown preclinical promise as a form of targeted therapy, inducing apoptosis selectively in t(4;14) positive HMCLs and t(4;14) positive multiple myeloma xenografts in mice (86–89).